ストックスクリーナーアプリを入手
2.14
7.54%
0.15
アフターアワーズ：
2.12
-0.02
-0.93%
前日終値:
$1.99
開ける：
$2.01
24時間の取引高:
2.39M
Relative Volume:
1.07
時価総額：
$208.90M
収益：
$32.31M
当期純損益:
$-237.09M
株価収益率:
-0.7431
EPS:
-2.88
ネットキャッシュフロー:
$-219.11M
1週間 パフォーマンス:
+4.90%
1か月 パフォーマンス:
-11.57%
6か月 パフォーマンス:
-16.73%
1年 パフォーマンス:
+49.65%
1日の値動き範囲:
$1.995
$2.15
1週間の範囲:
$1.95
$2.15
52週間の値動き範囲:
$0.9101
$4.5372
Editas Medicine Inc Stock (EDIT) Company Profile
EDIT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
EDIT
Editas Medicine Inc
|
2.14 | 194.26M | 32.31M | -237.09M | -219.11M | -2.88 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Editas Medicine Inc Stock (EDIT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-28 | 開始されました | H.C. Wainwright | Buy |
| 2024-12-16 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2024-12-13 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2024-12-13 | ダウングレード | Stifel | Buy → Hold |
| 2024-12-13 | ダウングレード | Truist | Buy → Hold |
| 2024-12-11 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2024-11-25 | ダウングレード | BofA Securities | Buy → Underperform |
| 2024-11-06 | アップグレード | Evercore ISI | In-line → Outperform |
| 2024-11-04 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2024-08-08 | アップグレード | BofA Securities | Neutral → Buy |
| 2024-05-09 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2023-10-24 | アップグレード | Citigroup | Neutral → Buy |
| 2023-10-18 | アップグレード | JP Morgan | Underweight → Neutral |
| 2023-10-17 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2023-09-29 | アップグレード | Stifel | Hold → Buy |
| 2023-06-12 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2023-02-01 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-12-13 | 開始されました | Citigroup | Neutral |
| 2022-12-06 | 再開されました | Credit Suisse | Neutral |
| 2022-11-18 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2022-11-18 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2022-09-29 | 開始されました | BofA Securities | Neutral |
| 2021-10-19 | 開始されました | SVB Leerink | Mkt Perform |
| 2021-09-24 | 開始されました | Stifel | Hold |
| 2021-09-10 | アップグレード | Oppenheimer | Perform → Outperform |
| 2021-08-09 | アップグレード | Truist | Hold → Buy |
| 2021-08-05 | アップグレード | Evercore ISI | Underperform → Outperform |
| 2021-06-04 | 再開されました | Robert W. Baird | Outperform |
| 2021-05-04 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2021-04-16 | 開始されました | Goldman | Sell |
| 2021-03-22 | 開始されました | Credit Suisse | Outperform |
| 2021-03-01 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2021-02-26 | ダウングレード | Truist | Buy → Hold |
| 2021-01-19 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2021-01-07 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2020-12-10 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2020-11-03 | 開始されました | Robert W. Baird | Underperform |
| 2020-06-18 | 再開されました | SunTrust | Buy |
| 2020-02-21 | 開始されました | Wells Fargo | Equal Weight |
| 2019-04-12 | 開始されました | Evercore ISI | Outperform |
| 2018-10-10 | 開始されました | Guggenheim | Neutral |
| 2018-09-21 | 開始されました | Raymond James | Outperform |
| 2018-05-15 | 繰り返されました | Chardan Capital Markets | Buy |
| 2018-02-13 | 開始されました | CLSA | Underperform |
| 2018-01-23 | アップグレード | SunTrust | Hold → Buy |
| 2017-07-14 | 開始されました | SunTrust | Hold |
| 2017-03-28 | 開始されました | Chardan Capital Markets | Buy |
| 2016-08-10 | アップグレード | Jefferies | Hold → Buy |
| 2016-06-02 | 開始されました | Jefferies | Hold |
| 2016-02-29 | 開始されました | JMP Securities | Mkt Outperform |
| 2016-02-29 | 開始されました | JP Morgan | Neutral |
| 2016-02-29 | 開始されました | Morgan Stanley | Equal-Weight |
すべてを表示
Editas Medicine Inc (EDIT) 最新ニュース
Editas Medicine, Inc. (NASDAQ:EDIT) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Fibonacci Retracement Aligns with Support in Alka Securities LimitedMarket Sentiment Shifts & Free Realize Exceptional Returns - earlytimes.in
Editas Medicine (NASDAQ:EDIT) Stock Price Down 2.9%Should You Sell? - MarketBeat
Editas Medicine (EDIT) price target increased by 22.78% to 4.95 - MSN
Can Editas Medicine Inc. stock attract ESG capital inflowsPortfolio Growth Summary & High Win Rate Trade Tips - Улправда
Is Editas Medicine Inc. stock overvalued by current metricsGap Up & Reliable Trade Execution Plans - Улправда
Editas Medicine Stock Slides After-Hours On Bigger-Than-Expected Q4 Loss, But Retail Bulls Eye M&A Potential - MSN
Can Editas Medicine Inc. stock surprise with earnings upsideJuly 2025 Patterns & Fast Exit and Entry Trade Guides - Улправда
Editas Medicine Earnings Notes - Trefis
What margin trends mean for Editas Medicine Inc. stockIPO Watch & Weekly Chart Analysis and Guides - DonanımHaber
How Editas Medicine Inc. stock compares to growth peersPortfolio Profit Report & Precise Entry and Exit Recommendations - Bölüm Sonu Canavarı
Is Editas Medicine Inc. stock affected by interest rate hikes2025 Market Outlook & Free Technical Pattern Based Buy Signals - DonanımHaber
Is Editas Medicine Inc. stock in correction or buying zoneJuly 2025 Catalysts & Expert Curated Trade Setups - DonanımHaber
Why Editas Medicine Inc. stock is seen as undervaluedOptions Play & Advanced Swing Trade Entry Alerts - DonanımHaber
Editas Medicine (LTS:0IFK) EV-to-FCF : -0.48 (As of Dec. 18, 2025) - GuruFocus
S P Trends: How Editas Medicine Inc stock compares to growth peersWeekly Profit Recap & Consistent Profit Trading Strategies - moha.gov.vn
Editas Medicine (FRA:8EM) EV-to-OCF : -0.45 (As of Dec. 18, 2025) - GuruFocus
Market Rankings: What margin trends mean for Editas Medicine Inc. stockIPO Watch & Capital Efficiency Focused Strategies - moha.gov.vn
Editas (EDIT) down 8.3% since last earnings report: Can it rebound? - MSN
What analysts say about Editas Medicine Inc stockTechnology Stock Trends & Small Budget Trading Plans - earlytimes.in
Editas (EDIT) Down 8.3% Since Last Earnings Report: Can It Rebound? - sharewise.com
Cell & Gene Therapy Market to Reach USD 105.83 Billion by 2033 - openPR.com
Editas Medicine, Inc. (NASDAQ:EDIT) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Editas Medicine (EDIT) Price Target Increased by 22.78% to 4.95 - Nasdaq
Editas Medicine (EDIT) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Editas Medicine (NASDAQ:EDIT) CEO Sells $12,046.45 in Stock - MarketBeat
Trend Recap: Is Editas Medicine Inc. (8EM) stock supported by free cash flowJuly 2025 Patterns & High Accuracy Swing Trade Signals - moha.gov.vn
What valuation ratios show for Editas Medicine Inc. (8EM) stockEarnings Summary Report & Reliable Intraday Trade Alerts - Newser
CEO O'Neill Surrenders 5,603 Of Editas Medicine Inc [EDIT] - TradingView
Editas Medicine CEO Sells Shares to Meet Tax Obligations - TradingView
How Editas Medicine Inc. (8EM) stock performs in easing cyclesJuly 2025 Selloffs & Safe Entry Momentum Tips - Newser
Editas Medicine (NASDAQ:EDIT) Shares Cross Below 50-Day Moving AverageTime to Sell? - MarketBeat
Will Editas Medicine Inc. (8EM) stock beat Nasdaq index returns2025 Pullback Review & Free Verified High Yield Trade Plans - Newser
Is Editas Medicine Inc. (8EM) stock positioned for digital growth eraMarket Growth Summary & Free Fast Gain Swing Trade Alerts - Newser
CEO O'Neill Files To Sell 7,000 Of Editas Medicine Inc [EDIT] - TradingView
Euro India Fresh Foods Limited Forms Bullish Flag Upside AheadCovered Call Writing & Learn From the Strategies of Institutions - earlytimes.in
FY2025 EPS Estimates for Editas Medicine Lowered by Analyst - MarketBeat
Editas Medicine (NASDAQ:EDIT) Stock Crosses Below 50-Day Moving AverageTime to Sell? - MarketBeat
Portfolio Shifts: Is Editas Medicine Inc. stock a bargain at current levelsMarket Activity Recap & Fast Moving Stock Trade Plans - moha.gov.vn
Editas (EDIT) Q2 2024 Earnings Call Transcript - The Globe and Mail
Editas Medicine Inc Stock Analysis and ForecastGeopolitical Risk Analysis & Access Free Risk Analysis Before You Invest - earlytimes.in
Editas Medicine (EDIT) Reports Q3 Loss, Beats Revenue Estimates - MSN
Editas Medicine price target raised to $4.60 from $4 at Clear Street - MSN
Is Editas Medicine Inc. (8EM) stock overpriced at current multiplesPortfolio Risk Report & Risk Controlled Swing Trade Alerts - newser.com
Is Editas Medicine Inc. (8EM) stock in buy zone after pullbackJuly 2025 Rallies & AI Powered Market Entry Strategies - newser.com
Will Editas Medicine Inc. (8EM) stock gain from green policies2025 Big Picture & Technical Confirmation Alerts - newser.com
Will Editas Medicine Inc. stock continue upward momentumForecast Cut & Free Technical Pattern Based Buy Signals - newser.com
How Editas Medicine Inc. (8EM) stock responds to job market shiftsJuly 2025 Snapshot & AI Enhanced Market Trend Forecasts - newser.com
Can Editas Medicine Inc. stock sustain market leadershipQuarterly Risk Review & Weekly Chart Analysis and Trade Guides - newser.com
Is Editas Medicine Inc. (8EM) stock expanding market penetrationFed Meeting & High Accuracy Swing Entry Alerts - newser.com
Does Editas Medicine Inc. (8EM) stock trade below intrinsic valueQuarterly Performance Summary & Verified Chart Pattern Trade Signals - newser.com
Editas Medicine Inc (EDIT) 財務データ
収益
当期純利益
現金流量
EPS
2.52%
0.07%
大文字化:
|
ボリューム (24 時間):